Clinical Trial Update: Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating AQW051 for cognitive function in patients with chronic stable schizophrenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• AQW051

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Schizophrenia Disorders | Phase 2 | Status: COMPLETED